Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MCRPC (metastatic Castration-resistant Prostate Cancer)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511
What this trial is testing

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 7
Testing effectiveness (Phase 2)UnknownNCT03356444
What this trial is testing

Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate

Who this might be right for
Prostate CancerCastration-resistant Prostate CancerDrug
West China Hospital 140
Not applicableUnknownNCT04746300
What this trial is testing

ImPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGS

Who this might be right for
Metastatic Prostate Cancer
Radboud University Medical Center 400
Large-scale testing (Phase 3)UnknownNCT05627752
What this trial is testing

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Who this might be right for
Prostate CancerCastrate Resistant Prostate Cancer
Zhongnan Hospital 120
Early research (Phase 1)Looking for participantsNCT03460977
What this trial is testing

Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer (SCLC)Follicular Lymphoma (FL)
Pfizer 453
Testing effectiveness (Phase 2)Looking for participantsNCT06533644
What this trial is testing

SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Syncromune, Inc. 91
Testing effectiveness (Phase 2)Looking for participantsNCT04104776
What this trial is testing

Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Who this might be right for
Advanced Solid TumorDiffuse Large B Cell LymphomaLymphoma, T-Cell+5 more
Novartis Pharmaceuticals 300
Early research (Phase 1)Looking for participantsNCT07641049
What this trial is testing

Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate CancerAdvanced Prostate AdenocarcinomaPSCA-positive Prostate Cancer+1 more
Beijing Biotech 36
Testing effectiveness (Phase 2)Study completedNCT03899467
What this trial is testing

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Suzhou Kintor Pharmaceutical Inc, 61
Early research (Phase 1)Study completedNCT03575819
What this trial is testing

FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Metastatic
Fortis Therapeutics, Inc. 56
Testing effectiveness (Phase 2)Study completedNCT02787005
What this trial is testing

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Merck Sharp & Dohme LLC 388
Very early researchLooking for participantsNCT07298239
What this trial is testing

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Castration-resistant Prostate Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 15
Testing effectiveness (Phase 2)Ended earlyNCT02379390
What this trial is testing

Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide

Who this might be right for
Prostate Cancer Metastatic
Sanofi 8
Early research (Phase 1)Study completedNCT03724747
What this trial is testing

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Bayer 63
Very early researchUnknownNCT03692663
What this trial is testing

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Allife Medical Science and Technology Co., Ltd. 9
Very early researchLooking for participantsNCT07798778
What this trial is testing

Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Affiliated Hospital of Jiangnan University 18
Testing effectiveness (Phase 2)Study completedNCT02217566
What this trial is testing

Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 46
Testing effectiveness (Phase 2)Ended earlyNCT02985021
What this trial is testing

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+1 more
Seattle Institute for Biomedical and Clinical Research 2
Early research (Phase 1)Looking for participantsNCT07660211
What this trial is testing

Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC）

Who this might be right for
PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VitsGen Therapeutics Inc. 10
Testing effectiveness (Phase 2)UnknownNCT03356912
What this trial is testing

CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Consorzio Oncotech 220
Next Page